Trial will evaluate DF-003, a first-in-class ALPK1 inhibitor that specifically targets the genetic root cause of ROSAH syndrome ...

CARLSBAD, CA, USA I August 04, 2025 I Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel ...

SOUTH SAN FRANCISCO, CA, USA I August 04, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – ...

MUNICH, Germany I August 04, 2025 I Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today ...

SAN FRANCISCO, CA, USA and SUZHOU, China I August 4, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...

OSLO, Norway I August 5, 2025 I Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced ...

CAMBRIDGE, MA, USA I August 04, 2025 I Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics inspired by ...

August 04, 2025 I PolTREG S.A. (Warsaw Stock Exchange: PTG), a pioneer in cell therapies for autoimmune diseases, and its U.S. subsidiary Immuthera, announced ...

LONDON, UK I August 05, 2025 I Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today ...

HONG KONG, China I August 4, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II ...

TAIPEI, Taiwan I August 4, 2025 I Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New ...